Abbott Laboratories (ABT)

Abbott Laboratories' stock performance has been influenced by earnings reports, shifts in product demand, and broader economic factors. In Q1 2025, Abbott reported adjusted EPS of $1.09, beating estimates, but worldwide sales of $10.36 billion missed consensus; the stock initially fell but later surged. In Q2 2025, Abbott reported adjusted EPS of $1.26, beating estimates, and worldwide sales of $11.14 billion, also surpassing expectations; the stock fell due to cautious third-quarter guidance. Potential impacts from new U.S. tariffs and China's volume-based procurement programs on diagnostics have been a recurring theme. Several analysts have maintained "Buy" or "Outperform" ratings, citing pipeline momentum and strong growth in medical devices and nutrition.

Demand for medical devices generally exhibits steady growth, driven by chronic diseases and advances in digital health. The diagnostics segment experiences increased global demand for routine diagnostic testing, offset by a decline in COVID-19 testing sales and procurement programs in China. There is strong global demand for adult nutrition products and continued strength in pediatric nutrition in the United States. The Established Pharmaceuticals Division (EPD) has demonstrated sustained growth in emerging markets.

Abbott Laboratories is a global healthcare company specializing in medical products, operating in the Health Care sector with primary industries in Medical Devices and Pharmaceuticals. Its major products include pharmaceuticals, diagnostic products, nutritional products, and medical devices. Pharmaceuticals include branded generic pharmaceuticals, anti-infectives, and influenza vaccines. Diagnostic products include core laboratory, molecular, point-of-care, and rapid diagnostics. Nutritional products include pediatric and adult nutrition products. Medical devices encompass rhythm management, electrophysiology, heart failure, structural heart, neuromodulation, and diabetes care products.

Abbott Laboratories has a significant global presence, operating in over 160 countries with its headquarters in Abbott Park, Illinois, U.S. It has an extensive network including manufacturing facilities, research and development centers, commercial offices, and distribution networks across North America, Latin America, Europe, Asia-Pacific, the Middle East, and Africa.

Abbott Laboratories has maintained a generally positive brand reputation, highlighted by its commitment to innovation and sustainability. The company was recognized for taking the top spot on the 2023 Dow Jones Sustainability Index (DJSI) for the 11th consecutive year, underscoring its strong performance in sustainability. No specific negative events significantly impacted Abbott Laboratories' brand reputation within the past year.

Abbott Laboratories is predominantly owned by institutional shareholders, who hold 79.10% of the company's stock. Insiders own 1.14%, and retail investors account for 19.75% of the ownership. The largest individual shareholder is Vanguard Group Inc., owning 9.93% of the company.